Back to search results

Study of Etentamig for Relapsed or Refractory Multiple Myeloma

This study is looking at a new treatment called etentamig for adults with multiple myeloma (MM) that has come back (relapsed) or hasn't responded to previous treatments (refractory). MM is a cancer of plasma cells in your blood, often found in bones. Researchers want to see how etentamig, given as an intravenous (IV) infusion, compares to standard treatments like carfilzomib, pomalidomide, elotuzumab, or selinexor. The study will measure how long people live without their cancer getting worse (Progression Free Survival) and how many see their cancer shrink or disappear (Objective Response Rate) over about 5 years. You may be able to join if you are 18 or older, have a good performance status, and have measurable disease.

Study design
This is an interventional study planning to enroll 380 participants. It has two arms: Arm A will receive etentamig alone, and Arm B will receive standard available therapies.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to approximately 5 years to measure how long they live without their cancer getting worse and how many see their cancer shrink or disappear.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06158841

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
AbbVie
~421 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:EtentamigCarfilzomibPomalidomideElotuzumabSelinexorBortezomib

At a glance

Recruiting sites
0 of 166 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Progression Free Survival (PFS)
Measured over Up to Approximately 5 Years
+1 more outcome measured

Conditions

Multiple Myeloma

Explore related trials

Multiple Myeloma

Where it's being run

166 sites across 109 states
California4
Illinois4
Michigan4
New York4
Tennessee4
Spain4
North Carolina3
Virginia3

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eastern Cooperative Oncology Group (ECOG) performance of \<= 2.
Diagnosis of relapsed/refractory (R/R) multiple myeloma (MM) during or after the participant's last treatment as stated in the protocol.
Must have measurable disease with at least 1 of the following assessed within 28 days of enrollment:
Serum M-protein \>= 0.5 g/dL (\>= 5 g/L).
Urine M-protein \>= 200 mg/24 hours.
In participants without measurable serum or urine M protein, serum free light chain (FLC) \>= 100 mg/L (10 mg/dL) (involved light chain)and an abnormal serum kappa lambda ratio.
Must have received at least 2 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide (IMiD), and an anti-CD38 monoclonal antibody (mAb).
Must be eligible to receive the Investigator's choice standard available therapy (SAT) based on approved prescribing information, previous MM treatment history, and institutional guidelines.

Exclusion

Clinically significant (per Investigator's judgment) drug or alcohol abuse within the last 6 months.
Clinically significant conditions such as but not limited to the following: neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months that would adversely affect the participant's participation in the study.
Central nervous system involvement of MM.
Has received B-cell maturation antigen (BCMA)-targeted therapy.

What this trial measures

  • Progression Free Survival (PFS)Up to Approximately 5 Years

    PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) determined by independent review committee (IRC) per international myeloma working group (IMWG) (2016) response criteria, or death, whichever occurs first.

  • Objective Response Rate (ORR)Up to Approximately 5 Years

    ORR is defined as the percentage of participants who achieve confirmed partial response (PR) + VGPR + complete response (CR) + stringent complete response (sCR) or per IRC assessment.